Search Results - "O'Dorisio, M"

Technical Note: Single time point dose estimate for exponential clearance by Madsen, Mark T., Menda, Yusuf, O'Dorisio, Thomas M., O'Dorisio, M. Sue

“…Objective Although personalized dosimetry may be desirable for radionuclide therapy treatments, the multiple time samples required to determine the total…”
Get full text

Evolution of Neuroendocrine Tumor Therapy by O’Dorisio, Thomas M., Harris, Alan G., O’Dorisio, M Sue

“…To better understand developments in treatment of neuroendocrine tumors of the gastroenteropancreatic system, and the pivotal roles of native somatostatin and…”
Get full text

Pancreastatin Predicts Survival in Neuroendocrine Tumors by Sherman, Scott K., Maxwell, Jessica E., O’Dorisio, M. Sue, O’Dorisio, Thomas M., Howe, James R.

“…Background Serum neurokinin A, chromogranin A, serotonin, and pancreastatin reflect tumor burden in neuroendocrine tumors. We sought to determine whether their…”
Get full text

Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors by Sherman, Scott K., MD, Carr, Jennifer C., MD, Wang, Donghong, MS, O’Dorisio, M. Sue, MD, PhD, O’Dorisio, Thomas M., MD, Howe, James R., MD

“…Background Ligands binding the somatostatin receptor type 2 (SSTR2) are useful for imaging and treatment of neuroendocrine tumors (NETs), but not all tumors…”
Get full text

Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors by Borbon, Luis C., Sherman, Scott K., Breheny, Patrick J., Chandrasekharan, Chandrikha, Menda, Yusuf, Bushnell, David, Bellizzi, Andrew M., Ear, P. H., O’Dorisio, M. Sue, O’Dorisio, Thomas M., Dillon, Joseph S., Howe, James R.

“…Peptide receptor radionuclide therapy (PRRT) is an effective treatment for advanced gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). We investigated…”
Get full text

The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer by Chen, Herbert, Sippel, Rebecca S, O'Dorisio, M Sue, Vinik, Aaron I, Lloyd, Ricardo V, Pacak, Karel

“…Pheochromocytomas, intra-adrenal paraganglioma, and extra-adrenal sympathetic and parasympathetic paragangliomas are neuroendocrine tumors derived from adrenal…”
Get full text

Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors by Sherman, Scott K., Maxwell, Jessica E., Carr, Jennifer C., Wang, Donghong, Bellizzi, Andrew M., Sue O’Dorisio, M., O’Dorisio, Thomas M., Howe, James R.

“…Small bowel (SBNETs) and pancreatic neuroendocrine tumors (PNETs) often present with liver metastases. Although liver biopsy establishes a neuroendocrine…”
Get full text

Addition of 131 I-MIBG to PRRT ( 90 Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors by Bushnell, David L, Bodeker, Kellie L, O'Dorisio, Thomas M, Madsen, Mark T, Menda, Yusuf, Graves, Stephen, Zamba, Gideon K D, O'Dorisio, M Sue

“…Peptide receptor radionuclide therapy (PRRT) is an effective treatment for metastatic neuroendocrine tumors. Delivering a sufficient tumor radiation dose…”
Get full text

Auranofin inhibition of thioredoxin reductase sensitizes lung neuroendocrine tumor cells (NETs) and small cell lung cancer (SCLC) cells to sorafenib as well as inhibiting SCLC xenograft growth by Johnson, Spenser S, Liu, Dijie, Ewald, Jordan T, Robles-Planells, Claudia, Pulliam, Casey, Christensen, Keegan A, Bayanbold, Khaliunaa, Wels, Brian R, Solst, Shane R, O'Dorisio, M Sue, Menda, Yusuf, Spitz, Douglas R, Fath, Melissa A

“…Thioredoxin Reductase (TrxR) functions to recycle thioredoxin (Trx) during hydroperoxide metabolism mediated by peroxiredoxins and is currently being targeted…”
Get full text

Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: Nine standard SEER registries, 1975-2006 by Navalkele, Pournima, O'Dorisio, M Sue, O'Dorisio, Thomas M., Zamba, Gideon K.D., Lynch, Charles F.

“…Background The incidence, survival, and prevalence of neuroendocrine tumors (NETs) in children were determined as a first step in improving diagnosis and…”
Get full text

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors by Halfdanarson, Thorvardur R., Strosberg, Jonathan R., Tang, Laura, Bellizzi, Andrew M., Bergsland, Emily K., O'Dorisio, Thomas M., Halperin, Daniel M., Fishbein, Lauren, Eads, Jennifer, Hope, Thomas A., Singh, Simron, Salem, Riad, Metz, David C., Naraev, Boris G., Reidy-Lagunes, Diane L., Howe, James R., Pommier, Rodney F., Menda, Yusuf, Chan, Jennifer A.

“…This article is the result of the North American Neuroendocrine Tumor Society consensus conference on the medical management of pancreatic neuroendocrine…”
Get full text

Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients by Theiler, Deborah, Cattaneo, Marco, Dierickx, Lawrence O, Igaz, Peter, Grozinsky-Glasberg, Simona, Bournaud, Claire, O'Dorisio, Thomas, O'Dorisio, M Sue, Wild, Damian, Christ, Emanuel, Nicolas, Guillaume P

“…Peptide receptor radionuclide therapy (PRRT) is a well-established treatment in somatostatin receptor-expressing neuroendocrine tumours (NETs). The safety and…”
Get full text

Chemokine Receptor CXCR4 Radioligand Targeted Therapy Using 177Lutetium-pentixather for Pulmonary Neuroendocrine Cancers by Fath, Melissa A., Liu, Dijie, Ewald, Jordan T., Robles-Planells, Claudia, Tomanek-Chalkley, Ann M., Graves, Stephen A., Howe, James R., O'Dorisio, Thomas M., Rastogi, Prerna, Bellizzi, Andrew M., O'Dorisio, M Sue, Menda, Yusuf, Spitz, Douglas R.

“…Intermediate to high-grade lung neuroendocrine tumors (NETs; i.e., atypical carcinoid tumors) and neuroendocrine carcinomas (NECs) are currently difficult to…”
Get full text

VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage by Abad, Catalina, Jayaram, Bhavaani, Becquet, Laurine, Wang, Yuqi, O'Dorisio, M Sue, Waschek, James A, Tan, Yossan-Var

“…Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) are two highly homologous neuropeptides. In vitro and ex vivo…”
Get full text

Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors by Bushnell, David L, Bodeker, Kellie L, O'Dorisio, Thomas M, Madsen, Mark T, Menda, Yusuf, Graves, Stephen, Zamba, Gideon KD, O'Dorisio, M Sue

“…Peptide receptor radionuclide therapy (PRRT) is an effective treatment for metastatic neuroendocrine tumors. Delivering a sufficient tumor radiation dose…”
Get full text

GIPR expression in gastric and duodenal neuroendocrine tumors by Sherman, Scott K., MD, Maxwell, Jessica E., MD, MBA, Carr, Jennifer C., MD, Wang, Donghong, MS, O'Dorisio, M. Sue, MD, PhD, O'Dorisio, Thomas M., MD, Howe, James R., MD

“…Abstract Background Compounds targeting somatostatin-receptor-type-2 ( SSTR2 ) are useful for small bowel neuroendocrine tumor (SBNET) and pancreatic…”
Get full text

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial by Yao, James C, Lombard-Bohas, Catherine, Baudin, Eric, Kvols, Larry K, Rougier, Philippe, Ruszniewski, Philippe, Hoosen, Sakina, St Peter, Jessica, Haas, Tomas, Lebwohl, David, Van Cutsem, Eric, Kulke, Matthew H, Hobday, Timothy J, O'Dorisio, Thomas M, Shah, Manisha H, Cadiot, Guillaume, Luppi, Gabriele, Posey, James A, Wiedenmann, Bertram

“…PURPOSE No established treatment exists for pancreatic neuroendocrine tumor (NET) progression after failure of chemotherapy. Everolimus (RAD001), an oral…”
Get full text

Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours by Bodei, L., Mueller-Brand, J., Baum, R. P., Pavel, M. E., Hörsch, D., O’Dorisio, M. S., O’Dorisio, T. M., Howe, J. R., Cremonesi, M., Kwekkeboom, D. J., Zaknun, J. J.

Get full text

Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted Therapy by Tran, Catherine G, Borbon, Luis C, Mudd, Jacqueline L, Abusada, Ellen, AghaAmiri, Solmaz, Ghosh, Sukhen C, Vargas, Servando Hernandez, Li, Guiying, Beyer, Gabriella V, McDonough, Mary, Li, Rachel, Chan, Carlos H F, Walsh, Susan A, Wadas, Thaddeus J, O'Dorisio, Thomas, O'Dorisio, M Sue, Govindan, Ramaswamy, Cliften, Paul F, Azhdarinia, Ali, Bellizzi, Andrew M, Fields, Ryan C, Howe, James R, Ear, Po Hien

“…Gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) are rare cancers consisting of neuroendocrine carcinomas (NECs) and neuroendocrine tumors (NETs),…”
Get full text

Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling by Carr, Jennifer C., MD, Boese, Erin A., BA, Spanheimer, Philip M., MD, Dahdaleh, Fadi S., MD, Martin, Molly, PhD, Calva, Daniel, MD, Schafer, Blanca, MS, Thole, David M., BS, Braun, Terry, PhD, O'Dorisio, Thomas M., MD, O'Dorisio, M. Sue, MD, PhD, Howe, James R., MD

“…Background Between 10% and 20% of patients with neuroendocrine tumors (NETs) present with metastases of unknown primary site. Because knowledge of the primary…”
Get full text